Diabetic macular oedema: a comparison of vitreous fluorometry, angiography, and retinopathy

B Sander, M Larsen, C Engler, C Strøm, B Moldow, N Larsen, H Lund-Andersen

Aim: To evaluate the relation between the quantitative measurement of vitreous fluorescein with fluorescein angiography and retinopathy in diabetic patients with and without clinically significant macular oedema (CSMO).

Methods: In a prospective cross sectional study, passive permeability and active, outward transport of fluorescein across the blood-retinal barrier were quantitated with vitreous fluorometry in 61 eyes from 48 patients with CSMO and 22 fellow eyes without CSMO, after exclusion of eyes with previous macular laser treatment and vitreous liquefaction. All patients were recruited from the university hospital's outpatient clinic. Retinopathy and fluorescein angiograms were evaluated on 60 degree photographs.

Results: The passive permeability in CSMO was significantly correlated with the severity of leakage on fluorescein angiograms (r=0.73), the level of retinopathy (r=0.61), and visual acuity (r=0.45). Significant differences between eyes with CSMO and eyes without CSMO were found for passive permeability (p<0.001), fluorescein leakage (p<0.001), visual acuity (p=0.02), and retinopathy (p=0.002).

Conclusion: Passive permeability of fluorescein quantitated with vitreous fluorometry was correlated both with semiquantitative fluorescein angiography and retinopathy, and a significant increase in passive permeability was found when comparing eyes with CSMO to eyes without CSMO. No such pattern was found for the active transport indicating that passive and not the outward, active transport is the factor of most importance in the development of CSMO.

Clinical data
The mean age of patients was 57 years (range 28–71) and duration of the disease 13 years (range 1–43). HbA1c was 8.8 (range 1–12), and systolic and diastolic blood pressures were 144 mm Hg (range 105–195) and 82 mm Hg (range 68–97), respectively, calculated as the mean of measurements every 3 months 1 year before the study.

Clinically significant macular oedema
CSMO was graded according to the ETDRS criteria as retinal thickening within 500 µm of the fovea, as hard exudates at/or within the same 500 µm if associated with retinal thickening, and as a >1 optic disc area of retinal thickening if any part of the oedematous area is within 1 disc diameter from the fovea. The grading was performed with biomicroscopy by an experienced retinal specialist and by a grader on stereoscopic fundus photographs. In five cases of disagreement the clinical grading was given priority.

SUBJECTS AND METHODS
Fifty three patients with CSMO in at least one eye were screened consecutively for a prospective study; 19 patients had type 1 and 34 had type 2 diabetes. The patients were recruited from the outpatient clinic of the department of ophthalmology at Herlev Hospital, University of Copenhagen, and the majority of the patients were regularly followed at the Steno Diabetes Center before referral to the department.

Exclusion criteria were proliferative retinopathy, cataract or pseudophakia, macular laser, and vitreous haemorrhage. In addition, vitreous detachment and/or posterior vitreous liquefication led to exclusion as calculation of passive and active transport is not possible in such eyes with the present methodology. Evaluated from the vitreous scans at 30 minutes, 16 eyes (five patients with liquefication in both eyes) were excluded a priori because of vitreous liquefication or posterior vitreous detachment.

Eighty three eyes from 48 patients fulfilled the inclusion/exclusion criteria, CSMO was found in 61 eyes and less or no retinal thickening in 22 eyes.
Retinopathy grading
Retinopathy was graded on 60 degree fundus photographs, using a procedure adapted to the modified Airlie House description. All patients had non-proliferative diabetic retinopathy (NPDR), ranging from mild to severe.

Fluorescein angiography
The filling phase of the fluorescein angiogram was recorded with a laser scanning ophthalmoscope (CLSO, Zeiss Germany) with 20 degree pictures in order to obtain maximum quality pictures of the foveal avascular zone. In all eyes examined (one eye in each patient) the diameter of the foveal avascular zone was below 1000 μm.

The later phases (2–3 minutes and 7–9 minutes) were obtained on 60 degree pictures from the Canon camera (CF-60UVi) and the severity of leakage was graded with a simplified procedure, based on the ETDRS system. The grading evaluates severity leakage at the geometric centre and the area of leakage in various distances from the fovea: the centre field within 500 μm, the inner field annulus between 500 μm and 1 disc diameter, and the outer field annulus between 1 and 2 disc diameters from the fovea. The far temporal field (>2 disc diameters from the fovea) was also graded. All fields were graded from standard photographs with the ETDRS classifications from 0 to 4 (0: no leakage, 1: questionable leakage, 2: definite, 3: moderate, 4: severe).

The fraction of leakage evaluated to originate from microaneurysms versus more diffuse leakage was also graded. The source of leakage was evaluated as either focal with >67% of the leakage originating from microaneurysms, diffuse with <33% from microaneurysms, and an intermediate group.

Vitreous fluorometry
The transport of fluorescein through the blood-retinal barrier is estimated from the preretinal fluorescein concentration curve and the concentration of free, unconjugated fluorescein in the plasma. Fluorescein is metabolised to another fluorescent molecule, fluorescein glucuronide, and in the study presented here both compounds are measured in plasma and in the vitreous with differential spectrophotometry. In the eye, fluorescein is measured along the optical axis using an ocular fluorometer (Fluorotron, OcuMetrics, San Jose, CA, USA). After a bolus injection of 14 mg/kg disodium fluorescein, post-injection scans were performed at 30 and 60 minutes for the calculation of the passive permeability of the blood-retinal barrier, and at 7, 8, 9, and 10 hours for the active transport (four scans at each session). Blood samples were obtained at each time point plus 5 and 15 minutes.
The study was approved by the local medical ethics committee. All participants gave their written informed consent after full information according to the Helsinki declaration.

RESULTS

Vitreous fluorometry and fluorescein angiography

The passive permeability compared to fluorescein angiography (in arbitrary units of severity times distance from the fovea) was significantly correlated both for eyes with and without CSMO (with CSMO: $r = 0.73$; $p < 0.001$, Fig 2; without CSMO: $r = 0.65$; $p < 0.001$).

The range of passive permeability in CSMO was large (Table 1) corresponding to the variation seen in angiograms. Examples of fluorescein angiograms for two eyes, both with CSMO, in one case associated with low passive permeability and for the other case associated with high permeability are shown in Figure 3.

Focal leakage—that is, leakage originating primarily from microaneurysms, was associated with lower passive permeability compared to intermediate or diffuse leakage, where leakage is found adjacent to dilated capillaries often widespread in the posterior pole (Fig 3). Passive permeability for focal, intermediate, and diffuse leakage was 5.18 nm/s, 19.81 nm/s, and 21.01 nm/s, respectively, the difference between groups was significant ($p < 0.001$; ANOVA). Active transport was not correlated with the fluorescein angiogram grading ($r = 0.1$).

Vitreous fluorometry and retinopathy

The passive permeability was significantly correlated with the level of retinopathy in CSMO (5.15 nm/s, 7.74 nm/s, 31.83 nm/s, and 20.28 nm/s for mild, moderate, moderate/severe, and severe retinopathy respectively, $p < 0.001$; ANOVA; Fig 4) and the same was found in eyes without CSMO (2.65 nm/s, 4.59 nm/s, 6.76 nm/s, and 2.93 nm/s for mild, moderate, moderate/severe, and severe retinopathy, respectively, $p = 0.045$; ANOVA). The active transport was not correlated with retinopathy ($p = 0.6$; ANOVA).

Vitreous fluorometry and visual acuity

A significant correlation was found between visual acuity (ETDRS) and passive permeability for eyes with CSMO ($r = 0.45$; $p < 0.001$). No significant correlation was found with regard to active transport ($r = 0.24$; $p = 0.07$).

The relation between visual acuity and fluorescein transport is illustrated in Figure 5 with a simplified visual acuity scale (below 30 letters (20/63), from 30 to 40 letters, 40 to 50 letters, and 50 letters or more (that is, from 20/25 and better)). For the active transport, no clear pattern is seen, as the largest active transport corresponds to a modest loss of visual acuity.

Clinical parameters

No significant correlations were found for fluorescein transport (neither passive nor active) and blood pressure or blood

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Passive permeability, active transport, and visual acuity for 61 eyes with CSMO and 22 eyes without CSMO</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSMO</td>
<td>Passive permeability (nm/s)</td>
</tr>
<tr>
<td>Mean</td>
<td>11.32*</td>
</tr>
<tr>
<td>95% confidence interval</td>
<td>8.7 to 14.7</td>
</tr>
<tr>
<td>Range</td>
<td>2–72</td>
</tr>
<tr>
<td>No CSMO</td>
<td>Mean</td>
</tr>
<tr>
<td>95% confidence interval</td>
<td>2.7 to 4.7</td>
</tr>
<tr>
<td>Range</td>
<td>1–13</td>
</tr>
</tbody>
</table>
| *Significant differences ($p<0.05$).

Figure 3 Examples of a patient with a small central clinically significant macular oedema with focal leakage (left side) and a patient with more widespread and diffuse leakage (right side). Focal leakage is defined as leakage originating predominantly (> 67%) from microaneurysms, while in diffuse leakage the estimated component from microaneurysms is less than 33%. The calculated passive permeability for the example on the left was 3.5 nm/s, for the example on the right the passive permeability was 21 nm/s.

Figure 4 Passive permeability (top) and active transport (bottom) versus retinopathy grading on fundus photographs in eyes with and without CSMO. All eyes had non-proliferative diabetic retinopathy (NPDR) with the levels mild, moderate, moderate to severe, and severe according to the ETDRS system. In all grades, mean passive permeability is higher in oedematous eyes, the difference is significant for moderate/severe and severe retinopathy. The passive permeability was significantly correlated with the degree of retinopathy, in eyes with and without CSMO ($p<0.001$ and $p = 0.045$ respectively, ANOVA). No such pattern was found for the active transport.
The **passive permeability** was not statistically different in eyes with and without oedema (62.12 nm/s and 71.95 nm/s respectively, \( p = 0.5 \), Table 1).

Angiographic leakage was statistically significantly different for eyes with CSMO and eyes without CSMO \( (p<0.001, \text{Fig 6}) \) with a larger overlap between the groups than for passive permeability.

**Retinopathy and visual acuity.** A higher degree of retinopathy was found in eyes with CSMO compared with eyes without CSMO \( (p = 0.002, \text{Mann-Whitney U test}) \).

As expected, visual acuity was significantly lower in eyes with CSMO than without \( (\text{logMAR} = 0.16 \text{ and } 0.04 \text{ respectively, corresponding to } 20/32 \text{ and } 20/20, \text{p} = 0.02) \).

**DISCUSSION**

In diabetic macular oedema, the passive permeability of fluorescein, quantitated with vitreous fluorometry, was closely correlated with the leakage evaluated with angiography. The passive permeability was also significantly different in eyes with and without CSMO; thus vitreous fluorometry seems to be valuable as an alternative end point in clinical studies.

A gradual increase in permeability was seen in eyes without CSMO and mild retinopathy progressing to CSMO with severe retinopathy and both for CSMO and eyes without CSMO, the passive permeability was significantly correlated with retinopathy. A decrease in passive permeability was found at the most severe level of retinopathy compared to moderate retinopathy; however, only one eye without CSMO was found in this group. The largest increase in passive permeability was found in eyes with CSMO when retinopathy changed from moderate to moderate/severe—that is, at the appearance of intraretinal microvascular abnormalities.

The increase in permeability in relation to retinopathy corresponds to the majority of studies with vitreous fluorometry. In one previous study of diabetic patients with different levels of retinopathy, presumably without oedema, the passive permeability was not correlated with fluorescein angiography leakage and the number of background retinopathy changes (microaneurysms, hard and soft exudates, haemorrhages). An increase was first noted in the preproliferative and proliferative stages. A reason for the lack of correlation in mild background retinopathy could be loss of sensitivity in the study, as data were analysed as the mean of right and left eye which may blur out differences in retinopathy.

In the present study, an overlap was found in both vitreous fluorometry and with angiographic leakage between CSMO and eyes without CSMO (Fig 6), though the overlap was substantially smaller with vitreous fluorometry. This is not surprising as retinal thickening is related to the tissue oncotic pressure of various electrolytes and proteins, whereas fluorescein leakage is an estimate of blood-retinal barrier leakage for a specific molecule. Thus, some discrepancy between retinal thickening and fluorescein leakage may be expected, as also demonstrated in a study with simultaneous assessment of fluorescein leakage and objective measurement of retinal thickness. Also, in some cases fluorescein leakage is only present in a very small area and the increase in permeability is small even if the criteria of CSMO are fulfilled.

The active transport, which is substantially larger than the passive permeability, was equal in eyes with and without CSMO. However, compared to healthy subjects in a previous study using the same method, the active transport was significantly increased. The capacity of the active transport system in the retinal pigment epithelium is high as shown in animal studies and it is possible that the level of active transport of fluorescein in the healthy eyes is below full capacity while intraretinal changes related to retinopathy alone and/or oedema stimulate the pump activity to near full capacity.

---

**Figure 5** Passive permeability and active transport versus visual acuity given as number of letters from the ETDRS chart (55 letters equals 20/20, five letters equals one line). A significant correlation was found between passive permeability and visual acuity (Pearson’s \( r = 0.45, \text{p <0.001} \)) but not for visual acuity and active transport (Pearson’s \( r = 0.24, \text{p = 0.07} \)).

**Figure 6** Passive permeability (top) and angiographic leakage (bottom) in eyes without CSMO and with CSMO, mean (back transformed from the logarithmic scale) is indicated with a horizontal line. The difference between eyes with CSMO and eyes without CSMO was significant for both methods (\( p <0.001 \)).

---

**CSMO and non-CSMO**

The **passive permeability** of fluorescein was four times larger from eyes with CSMO compared with eyes without CSMO \( (P \text{max} \text{, } 11.32 \text{ nm/s and } 3.57 \text{ nm/s respectively, } p <0.001; \text{Table 1, Fig 6}) \).

The **passive permeability** of the metabolite fluorescein glucuronide was also larger in significant oedema (CSMO: 10.71 nm/s, no CSMO: 5.76 nm/s, \( p = 0.003 \)) and the permeability of the fluorescein and fluorescein glucuronide was correlated \( (r = 0.7, \text{p<0.001}) \).
In severe retinopathy, the active transport in the present study decreased non-significantly in eyes with CSMO and moderate to severe level of retinopathy (Fig 4); additionally, a decrease of active transport was seen in eyes with low visual acuity (Fig 5). Thus, one might speculate whether the active transport is exhausted in late stages of macular oedema.

Blood pressure and metabolic regulation were not correlated with passive or active transport, whereas passive permeability was negatively correlated with the duration of disease. In contrast, epidemiological studies have found that macular oedema is associated with high blood pressure and long duration of diabetes. The apparent differences from our results are probably the result of the presence of patients with type 2 diabetes, diagnosed late in relation to onset of the disease and already having retinopathy and/or CSMO at diagnosis or soon after. The expected correlation of passive permeability with blood pressure and duration cannot be expected in such patients, untreated for many years before diagnosis, similar to the study of Lawson et al., where blood pressure, glucose control, and duration were not associated with the severity of macular oedema evaluated as loss of visual acuity.

In summary, the breakdown of the blood-retinal barrier and the following increase in passive permeability measured with vitreous fluorometry is a dominant factor in diabetic macular oedema and, unlike active transport, the passive permeability is correlated with fluorescein angiogram leakage, retinopathy, and visual acuity. Thus, treatment of macular oedema should focus on the passive permeability. The exact mechanisms relating blood-retinal barrier breakdown to retinal thickening are not known, but recent studies have accentuated the role of vascular endothelium growth factor (VEGF) induced hyper-permeability, which seems related to changes in tight junction proteins (occludin) and upregulation of retinal adhesion molecule (ICAM-1), coincident with leucostasis. High levels of VEGF are found in proliferative retinopathy in humans and animal studies have shown an increased leakage of fluorescein from retinal vessels after injection of VEGF in the vitreous associated with an increased vesicular transport in endothelial cells. However, human studies in relation to diabetic macular oedema have not yet been completed.

ACKNOWLEDGMENTS
The study was funded by the Danish Diabetes Association, Odense, and the Danish Eye Health Society, Copenhagen. The authors thank Hans-Henrik Petersen for photographic assistance.

Authors’ affiliations
B Sander, M Larsen, C Engler, C Stram, B Moldow, H Lund-Andersen, Department of Ophthalmology, Herlev Hospital, University of Copenhagen, Dk 2730 Herlev, Denmark
N Larsen, Steno Diabetes Center, Niels Steensensvej 2, Dk 2820 Gentofte, Denmark

REFERENCES